Press Releases

May 9, 2019 in Press Release

NeuroPace Shares Positive Data from Studies of the RNS System at the American Academy of Neurology 2019 Annual Meeting

Results Demonstrate Significant Seizure Reduction in Adults with Drug-Resistant Epilepsy; Insights into the Human Brain MOUNTAIN VIEW, Calif. — May 9, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, presented long-term clinical results demonstrating that the RNS® System for refractory epilepsy significantly reduces seizure frequency in patients, with... Read More
May 2, 2019 in Press Release

NeuroPace to Present Data from Studies of the RNS System at 2019 American Academy of Neurology Annual Meeting

Presentations to highlight nine-year treatment outcomes and research on the potential use of electrographic data to identify RNS System responders MOUNTAIN VIEW, Calif. — May 2, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that data from two studies of the company’s RNS® System for adults... Read More
February 12, 2019 in Press Release

NeuroPace Announces New Category I CPT Code from AMA for Electrocorticography from an Implanted Brain Neurostimulator

Supports Value of Insights Provided by Brain Recordings from the NeuroPace RNS® System for Drug-Resistant Epilepsy MOUNTAIN VIEW, Calif. — February 12, 2019 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced that the American Medical Association (AMA) has issued a new Category I Current Procedural Terminology (CPT®)... Read More
December 2, 2018 in Press Release

NeuroPace Announces Final Results from the Largest Prospective Clinical Study in the Field of Neuromodulation with 9-Year Follow-Up at the 2018 American Epilepsy Society Annual Meeting

More than One-Third of Drug-Resistant Epilepsy Patients Achieved ≥90% Seizure Reduction with the RNS System. NEW ORLEANS--(BUSINESS WIRE)--American Epilepsy Society Annual Meeting, Booth 519 — NeuroPace, Inc., a Silicon Valley-based medical technology company that recently launched the Next-Gen RNS® System for refractory epilepsy, today announced complete results from its groundbreaking... Read More
June 1, 2018 in Press Release

NeuroPace Launches Next Generation RNS System, the World’s Only Brain-Computer Interface for the Treatment of Refractory Epilepsy

Next Gen RNS System provides unprecedented brain data with long-lasting, 8-year battery life. MOUNTAIN VIEW, Calif -- June 1, 2018 – NeuroPace, Inc., a Silicon Valley-based medical technology company, today announced the launch of its Next Gen RNS® System for the treatment of refractory epilepsy, which affects an estimated 1... Read More
December 5, 2017 in Press Release

NeuroPace Unveils 8-Year Prospective Clinical Outcomes and Groundbreaking Research Using Deep Learning Algorithms to Identify Seizure Biomarkers

WASHINGTON–(EON: Enhanced Online News)–American Epilepsy Society Annual Meeting, Booth 1101–NeuroPace, Inc., a Silicon Valley-based medical technology company that developed the world’s first and only closed-loop brain-responsive neurostimulation system for epilepsy, today announces 5 poster presentations, including new 8-year prospective clinical trial data presented at the American Epilepsy Society’s (AES) Annual…

Read More